Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II |
| |
| Authors: | Timothy M. E. Davis Jane Kauhanen Wendy A. Davis |
| |
| Affiliation: | 1. School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia;2. Department of Endocrinology and Diabetes, Fremantle Hospital, Fremantle, Western Australia, Australia |
| |
| Abstract: | ![]()
Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5‐yearly doses. In 1465 representative community‐based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self‐reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub‐optimal coverage. |
| |
| Keywords: | type 2 diabetes pneumococcal vaccination community‐acquired pneumonia |
|
|
